The latest developments from pharmaceutical and biopharmaceutical companies, both innovator and generic-drug companies, and leading regulatory news.
Thermo Fisher Scientific reports that its $12-billion-plus offer to Qiagen, a provider of molecular diagnostics and sample preparation technologies, has lapsed after failing to acquire the needed number of shares to effectuate the...
The latest on manufacturing and potential treatments for COVID-19 with news from Pfizer, Gilead Sciences, AstraZeneca, Takeda, Novavax, Daiichi Sankyo, and others.
Pfizer in Pact to Manufacture Gilead’s Remdesivir for COVID-19Pfizer has entered...
Eisai's US subsidiary, Eisai Inc., has announced plans to re-locate its US headquarters in Woodcliff Lake, New Jersey to the former Roche headquarters campus in Nutley, New Jersey. The move is expected to be completed in late 2021 and will transfer...
Moderna, a clinical-stage biopharmaceutical company developing messenger RNA (mRNA) therapeutics and vaccines, has been awarded up to $1.525 billion, including incentive payments, by the US government to manufacture and deliver 100 million doses of...
The US government is putting on hold a $765-million loan to Eastman Kodak Company, which was to be used to launch Kodak Pharmaceuticals, a new arm of the company to produce generic active pharmaceutical ingredients (APIs) in the US, pending a...
Bayer has agreed to acquire KaNDy Therapeutics, a Stevenage, UK-based clinical-stage biopharmaceutical company, to expand its drug-development pipeline in women’s healthcare, in a deal worth up to $875 million.
KaNDy Therapeutics recently...
A roundup of news from Germany (Evotec, Secarna Pharmaceuticals, CureVac), Japan (Teva, Takeda), and the US (Astellas, Sorrento Therapeutics, and SRI Biosciences).
Germany
Evotec, Secarna Pharmaceuticals in Pact for Antisense...
The latest on manufacturing and potential treatments for COVID-19 with news from Eli Lilly and Company, Pfizer, Amgen, AbbVie, Takeda, BioNTech, Novavax, and others.
Lilly Initiates Phase III Trial of Monoclonal Antibody for COVID-19 Eli Lilly and...
Novartis and Sangamo Therapeutics, a Brisbane, California-based genomic medicine company, have formed a global licensing collaboration agreement, worth up to $795 million, to develop and commercialize gene-regulation therapies to address three...
Merck & Co. and Hanmi Pharmaceutical, a Seoul, South Korea-based pharmaceutical company, have formed an exclusive licensing agreement, in a deal worth up to $870 million, for the development, manufacture and commercialization of efinopegdutide,...
Johnson & Johnson’s (J&J) Janssen Pharmaceutical Companies have entered into a $1-billion agreement with the US government for the large-scale domestic manufacturing and delivery in the US of 100 million doses of Janssen’s SARS-CoV-2...
Sanofi and GlaxoSmithKline (GSK) has formed a $2.1-billion pact with the US government for the development and manufacturing of their COVID-19 vaccine candidate and are in advanced discussions with the European Commission for the supply of up to...
Elanco Animal Health, the former animal-health business of Eli Lilly and Company and now a stand-alone company, has closed its $6.89-billion acquisition of Bayer Animal Health.
The companies signed an agreement for the acquisition in August 2019....
The latest on manufacturing and potential treatments for COVID-19 with news from Pfizer, J&J, Gilead Sciences, Genentech, Inovio, and Glenmark.
US DOJ OKs Info-Sharing on mAb Mfg Among Pharma Companies The US Department of Justice (DOJ) says...
Sanofi and GlaxoSmithKline (GSK) have reached an agreement, subject to a final contract, with the UK government for the supply of up to 60 million doses of a COVID-19 vaccine developed by Sanofi in partnership with GSK. The vaccine is based on...
